Full-Time

Senior Director Chemical Development

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$230k - $277.8k/yr

Belmont, MA, USA

In Person

On-site in Watertown, MA. Up to 20% travel to CDMOs domestically and internationally.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Treeline Biosciences

See people who can refer or advise you

Requirements
  • Ph.D. in Organic Chemistry, Chemical Engineering, or related discipline with a minimum of 12+ years of experience, or a Master’s with a minimum of 15+ years of experience in small molecule drug substance development
  • Track record of success in leading and managing small-molecule drug substance programs in a 100% outsourced environment
  • Strong vendor/supplier management skills and excellent communication and cross-functional collaboration skills
  • Competency in developing, implementing and delivering CMC project plans (milestones, timelines, resources, etc.) to successful endpoints
  • Expertise in authoring and reviewing technical documents including, but not limited to, development reports, master batch records, analytical testing methods, and specifications
  • Thorough knowledge of the drug development process and ICH requirements for NDA and MAA registration. Extensive experience in working with regulatory authorities. Track record of authoring and defending Module 3 CTD content through regulatory approval and commercialization
  • Ability to articulate complex issues and ideas with clarity to enable understanding and decision making
  • Pragmatic, solution-oriented thinker who possesses a “can do” and “whatever it takes” attitude, coupled with excellent organizational and communication skills
  • Strong interpersonal and decision-making skills with the ability to motivate and influence others, negotiate during situational conflict, and establish the best forward path in the face of competing points of view
  • Understanding of industry trends, practices, techniques and standards, and associated impact on program strategy and execution
  • Ability to travel (20%) to CDMO domestic and international sites
  • Fluency with standard computer software packages (MS Word, Excel, PowerPoint, and Project) and JMP (or similar statistical tools)
  • High level of personal integrity, commitment to excellence and to our patients
  • Experience in developing and commercializing drugs for oncology is preferred
Responsibilities
  • Lead and manage cross-functional teams engaged in external cGMP manufacturing of drug substance, DS intermediates, and starting materials
  • Provide technical and functional project leadership on drug substance process development, manufacturing, and CDMO partner management
  • Lead and manage process transfers and associated site implementation to support supply chain expansion activities and continuous improvement initiatives
  • Monitor, track and trend process performance. Develop and implement data analytics to support investigations and provide an historical baseline for future operational and process-related improvements
  • Support investigations, root cause identification and CAPA implementation associated with manufacturing deviations and associated quality events
  • Work closely with Analytical Development/QC, Quality Assurance, Regulatory CMC, Supply Chain and external manufacturing operations to ensure operational excellence with respect to timelines, budgets, and attainment of technical, regulatory and business goals/milestones
  • Lead the selection of drug substance CDMOs based upon core capabilities, capacity and track record of regulatory compliance; establish KPIs to monitor site technical, quality and business performance
  • Develop and maintain strong relationships with CDMO business partners and participate in Steering Committees as appropriate
  • Review/approve technical reports, controlled GMP documents and CMC content for Module 3 CTDs
  • Develop and manage scope, milestones, interdependencies, budgets and timelines associated with drug substance program deliverables. Ensure cross-functional alignment of drug substance program deliverables with overall program strategy
  • Continuously monitor external business and regulatory environments; identify risks and establish mitigation plans and/or best practices to proactively address Drug Substance and supply chain risk
  • Represent the Technical Operations organization in meetings with FDA, EMA and related regulatory authorities
Desired Qualifications
  • Experience in oncology drug development and commercialization is preferred

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Get referred to Treeline Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Treeline started three Phase 1 trials and planned a fourth in 2026.
  • The company closed a $200 million extension, reaching $1.1 billion total funding.
  • FTC early terminated HSR review on July 21, 2026, easing merger timing.

What critics are saying

  • The reverse-merger structure triggered shareholder investigations in June 2026 over fairness.
  • Treeline still lacks approved products; Phase 1 oncology data remains unproven.
  • If TLN-121, TLN-254, and TLN-372 disappoint, Treeline becomes a cash-burning shell.

What makes Treeline Biosciences unique

  • Josh Bilenker and Jeff Engelman built Treeline from Loxo Oncology experience.
  • Treeline advanced three Phase 1 oncology programs by September 2025.
  • The June 2026 Standard BioTools merger brings over $900 million pro forma cash.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

1%
My Malone Telegram
Jun 19th, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN)...

BRODSKY & SMITH SHAREHOLDER UPDATE: notifying investors of the following investigations: AstroNova, Inc. (Nasdaq - ALOT), Open Lending Corporation (Nasdaq - LPRO), Huntsman Corporation (NYSE - HUN), Standard BioTools Inc. (Nasdaq - LAB). * Jun 19, 2026 BALA CYNWYD, Pa., June 19, 2026 (GLOBE NEWSWIRE) - Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you. AstroNova, Inc. (Nasdaq - ALOT) Under the terms of the Merger Agreement, AstroNova will be acquired by Arcline Investment Management for $29.00 per share in cash in an all-cash transaction with a total enterprise value of approximately $272 million. The investigation concerns whether the AstroNova Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Open Lending Corporation (Nasdaq - LPRO) Under the terms of the Merger Agreement, Open Lending will be acquired by ANV Group Holdings Ltd. for $3.15 per share. The investigation concerns whether the Open Lending Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Huntsman Corporation (NYSE - HUN) Under the terms of the Merger Agreement, Huntsman will be acquired by Olin Corporation (NYSE - OLN) whereby Huntsman shareholders will receive 0.5476 shares in Olin for every one (1) share of Huntsman. Upon completion of the transaction, Olin shareholders will own approximately 54.5% and Huntsman shareholders will own approximately 45.5% of the combined company. The investigation concerns whether the Huntsman Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Standard BioTools Inc. (Nasdaq - LAB) Under the terms of the Merger Agreement, Standard BioTools will be acquired by Treeline Biosciences, Inc. At the closing of the proposed combination, pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, and pre-merger Treeline stockholders are expected to own approximately 84% of the combined company. The investigation concerns whether the Standard BioTools Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders. Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Endpoints News
Jun 8th, 2026
Treeline to go public via reverse merger with Standard BioTools.

Treeline to go public via reverse merger with Standard BioTools. News reporter. Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company... Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

GlobeNewswire
Jun 8th, 2026
Standard BioTools and Treeline Biosciences Announce Merger Agreement

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy...

Endpoints News
Sep 3rd, 2025
Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.

Business Wire
Sep 3rd, 2025
Treeline Biosciences Secures $200M, Starts Trials

Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.